Cardiac magnetic resonance left atrioventricular coupling index as a prognostic tool in hypertrophic cardiomyopathy

Jinyang Wen1, Junhao Tu2, Xinwei Tao3

  • 1Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ESC Heart Failure
|February 5, 2025
PubMed

Insights

The novel left atrioventricular coupling index (LACI) effectively predicts adverse outcomes in hypertrophic cardiomyopathy (HCM) patients. This cardiac MRI marker is superior to traditional measures for identifying high-risk individuals.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Biomarker Discovery

Background:

  • The left atrioventricular coupling index (LACI) is a novel marker associated with cardiovascular events in general populations.
  • Limited research exists on cardiac magnetic resonance (CMR)-derived LACI in hypertrophic cardiomyopathy (HCM) patients.
  • The prognostic value of LACI in HCM requires further thorough investigation.

Purpose of the Study:

  • To explore the association between LACI and adverse clinical outcomes in patients with HCM.
  • To evaluate the prognostic value of CMR-derived LACI in HCM.
  • To compare the predictive performance of LACI against conventional parameters.

Main Methods:

  • Retrospective enrollment of 206 HCM patients who underwent CMR examination.
  • LACI calculated as the ratio of left atrial (LA) to left ventricular (LV) volumes at LV end-diastole.
  • Composite endpoint included death, heart failure, and arrhythmia events; multivariable Cox regression and ROC analysis were employed.

Main Results:

  • LACI was identified as an independent predictor of composite events in HCM patients (HR 1.054, P < 0.001) after adjusting for age and atrial fibrillation.
  • An optimal LACI cut-off of 40.09% was determined for risk stratification.
  • Integrating LACI into a clinical model significantly improved risk prediction (C-statistic 0.892, NRI 0.627, IDI 0.295) compared to LA diameter, LAEF, LAVI, and LGE extent.

Conclusions:

  • LACI is an independent risk factor for adverse clinical outcomes in HCM patients.
  • LACI demonstrates superior performance in identifying high-risk HCM patients compared to conventional LA parameters and late gadolinium enhancement (LGE) extent.
  • CMR-derived LACI holds significant prognostic value in HCM.
Abstract

Related Concept Videos

Mitral Regurgitation II: Clinical Features and Diagnostic Tests01:23

Mitral Regurgitation II: Clinical Features and Diagnostic Tests

Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
843
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
485
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
978
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
801
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
767
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
695